Olivia H. Chen , Wesley K.Y. Wong , Kevin K.S. Mok , Landon L. Chan , Candy Tang , Molly S.C. Li
{"title":"Osimertinib-Related QTc Prolongation: Real-World Incidence and Impact of Drug Dosing on Recurrence Risk","authors":"Olivia H. Chen , Wesley K.Y. Wong , Kevin K.S. Mok , Landon L. Chan , Candy Tang , Molly S.C. Li","doi":"10.1016/j.cllc.2024.06.012","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>In a real-world retrospective study of 970 patients treated with osimertinib, incidence of grade 3 QTc prolongation was 0.9% which was similar to clinical trials. No events of ventricular arrhythmia or arrhythmia-related deaths were observed.</div></span></li><li><span>•</span><span><div>Baseline QTc prolongation (QTc ≥450ms) may be a potential risk factor for osimertinib-related grade 3 QTc prolongation.</div></span></li><li><span>•</span><span><div>In patients with grade 3 osimertinib-related QTc prolongation, rechallenging osimertinib at 80mg daily dose confers high recurrence risk while dose reduction mitigates recurrence risk.</div></span></li></ul></div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"25 8","pages":"Pages 738-743.e2"},"PeriodicalIF":3.3000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730424001372","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
•
In a real-world retrospective study of 970 patients treated with osimertinib, incidence of grade 3 QTc prolongation was 0.9% which was similar to clinical trials. No events of ventricular arrhythmia or arrhythmia-related deaths were observed.
•
Baseline QTc prolongation (QTc ≥450ms) may be a potential risk factor for osimertinib-related grade 3 QTc prolongation.
•
In patients with grade 3 osimertinib-related QTc prolongation, rechallenging osimertinib at 80mg daily dose confers high recurrence risk while dose reduction mitigates recurrence risk.
期刊介绍：
Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
